FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DRREDDY

3,904.3
+7.7 (0.2%)
Updated 03:29 10/07 IST

DRREDDY Buy or Sell - FrontPage Forums

4 Users have submitted 4 trade ideas of Rs. 50,819.3 for DRREDDY
Disclaimer
75% Bullish
25% Bearish

DRREDDY Buy or Sell - Brokerage Reports

No. of reports in last year
18
No. of analysts
7
Average Consensus Forecast
3330.22
Consensus Potential
-18.88%
See DRREDDY Share Price Targets >>

DRREDDY Ratings

Long term DRREDDY rating by FrontPage users
4.5/5 (11 Ratings)
Find answers to all your questions on live DRREDDY message board: Is DRREDDY buy or sell? Should I buy DRREDDY shares? Why are DRREDDY shares falling? Should I invest in DRREDDY stock?

  1. Home
  2. DRREDDY Forum

DRREDDY Share Price Discussion

INTRADAY TADKA in DRREDDY
FUTURE LOVER #DRREDDY FUT BUY ABOVE 3940 TGT URS
Like
Reply

DRREDDY - 1011862
Performance for the week
Drreddy ce4000* cmp 111.00 buy upto 70.00 stop 62.00 target 188.00+
Entry 88 to 124.50
*Profit ₹ 9,125*
2
Reply
N
Reputation: 3,975 • Jul 10 11:03 AM
Indian pharma market contracts nearly 6% in Q1FY21
Chronic segment that includes drugs for cardiovascular, diabetes, and neuro saw a slump in sales in Q1FY21 due to pre-emptive buying in March
Moneycontrol
Like
Reply
M
Reputation: -20,385 • Jul 10 8:11 AM

Type
Buy
Instrument
DRREDDY JUL20 3850 PE
Entry Price
₹127
Price@Trade
₹127
Target Price
₹186
Stop Price
₹95
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹31,750 approx for 250 Qty
Status
Active
Like
Reply
K
Reputation: 2,172,771 • Jul 10 6:18 AM
Like
Reply (1)
Latest replies
Raphael  @raphael
Jul 10 6:19 AM

It's going down..

Type
Sell
Instrument
DRREDDY JUL20 FUT
Entry Price
₹3,907  ₹3,908
Price@Trade
₹3,908
Target Price
₹3,880
Stop Price
₹3,930
Valid Till
Jul 10, 2020 3:20 AM
Margin
₹196,930.75 approx for 250 Qty
Status
Exited
Exit Price
₹3,915.05
Net P&L
-₹1,762.5 (-0.89%)
Like
Reply (3)
Latest replies

Update
Entry Price Modified
Price @ Update
₹3,908
Original Entry Price
₹3,907
New Entry Price
₹3,908
TrackerBot @trackerbot
Jul 10 4:46 AM

Update
Trade Entered
Entry Price
₹3,908

Update
Exited
Exit Price
₹3,915.05
Net P&L
-₹1,762.5 (-0.89%)

Type
Buy
Instrument
DRREDDY JUL20 FUT
Entry Price
₹3,930  ₹3,920
Price@Trade
₹3,938.8
Target Price
₹3,980
Stop Price
₹3,890
Valid Till
Jul 10, 2020 3:20 AM
Margin
₹395,252.5 approx for 500 Qty
Status
Exited before entry
Like
Reply (3)
Latest replies

Update
Entry Price Modified
Price @ Update
₹3,937.5
Original Entry Price
₹3,930
New Entry Price
₹3,937.5

Update
Entry Price Modified
Price @ Update
₹3,929
Original Entry Price
₹3,937.5
New Entry Price
3920.0

Update
Exited before entry
Price @ Update
₹3,910.8

FUTURE LOVER
#DRREDDY FUT BUY ABOVE 3940 TGT URS
Like
Reply (1)
Latest replies
Gowtham @gowtham-H1joJKQpU
Jul 10 6:51 AM

what sir drl going down any possiblity to take upper...
K
Reputation: 1 • Jul 9 8:19 AM

Type
Buy
Instrument
DRREDDY
Entry Price
₹3,893.55
Price@Trade
₹3,893.55
Target Price
₹4,300
Stop Price
₹3,500
Valid Till
Aug 7, 2020 3:20 AM
Margin
₹3,893.55 approx for 1 Qty
Status
Active
Like
Reply
N
Reputation: 3,975 • Jul 9 7:38 AM
A V-shape recovery unlikely; brokerages are betting on these 10 largecaps
Interventions by governments and central banks have prevented the economic situation from deteriorating significantly, it is unlikely that the recovery will be a V-shaped one, say experts.
Moneycontrol
Like
Reply
R
Reputation: 1,107 • Jul 9 3:36 AM

Cash Call
Buy Drreddy above 3905
tgt Open
sl 3870
Like
Reply

OPTION LOVER
#DRREDDY OPT BUY 3950 CE ABOVE 118 TGT 127 SL 113
Like
Reply

Type
Sell
Instrument
DRREDDY
Entry Price
₹3,938
Price@Trade
₹3,936.3
Target Price
₹3,920
Stop Price
₹3,944
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹393,800 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹3,944
Net P&L
-₹600 (-0.15%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 8 4:18 AM

Update
Trade Entered
Entry Price
₹3,938
TrackerBot @trackerbot
Jul 8 4:25 AM

Update
Stoploss Hit
Exit Price
₹3,944

Type
Sell
Instrument
DRREDDY
Entry Price
₹3,935
Price@Trade
₹3,927.3
Target Price
₹3,920
Stop Price
₹3,941
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹393,500 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹3,941
Net P&L
-₹600 (-0.15%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 8 4:15 AM

Update
Trade Entered
Entry Price
₹3,935
TrackerBot @trackerbot
Jul 8 4:16 AM

Update
Stoploss Hit
Exit Price
₹3,941

Type
Sell
Instrument
DRREDDY
Entry Price
₹3,928.5
Price@Trade
₹3,929
Target Price
₹3,910
Stop Price
₹3,930.5
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹196,425 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹3,930.5
Net P&L
-₹100 (-0.05%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 8 4:12 AM

Update
Trade Entered
Entry Price
₹3,928.5
TrackerBot @trackerbot
Jul 8 4:14 AM

Update
Stoploss Hit
Exit Price
₹3,930.5
V
Reputation: -1,446 • Jul 8 4:02 AM

Type
Buy
Instrument
DRREDDY JUL20 FUT
Entry Price
₹3,894  ₹3,899
Price@Trade
₹3,897
Target Price
₹3,940
Stop Price
₹3,870
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹584,780.56 approx for 750 Qty
Status
Exited
Exit Price
₹3,918
Net P&L
+₹14,250 (+2.44%)
Like
Reply (5)
Latest replies
Vardhan Jp @vardhanjp
Jul 8 4:02 AM

Update
Entry Price Modified
Price @ Update
₹3,897.15
Original Entry Price
₹3,894
New Entry Price
₹3,897.15
Vardhan Jp @vardhanjp
Jul 8 4:02 AM

Update
Entry Price Modified
Price @ Update
₹3,899.55
Original Entry Price
₹3,897.15
New Entry Price
₹3,899.55
Vardhan Jp @vardhanjp
Jul 8 4:04 AM

Update
Entry Price Modified
Price @ Update
₹3,899
Original Entry Price
₹3,899.55
New Entry Price
₹3,899
TrackerBot @trackerbot
Jul 8 4:05 AM

Update
Trade Entered
Entry Price
₹3,899
Vardhan Jp @vardhanjp
Jul 8 4:16 AM

Update
Exited
Exit Price
₹3,918
Net P&L
+₹14,250 (+2.44%)
A
Reputation: -1,994 • Jul 8 3:14 AM

Type
Buy
Instrument
DRREDDY JUL20 FUT
Entry Price
₹3,856.8
Price@Trade
₹3,856.8
Target Price
₹4,300
Stop Price
₹3,700
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹194,505 approx for 250 Qty
Status
Exited
Exit Price
₹3,917.15
Net P&L
+₹15,087.5 (+7.76%)
Like
Reply (1)
Latest replies
Aims @aims
Jul 8 4:21 AM

Update
Exited
Exit Price
₹3,917.15
Net P&L
+₹15,087.5 (+7.76%)
Like
Reply (1)
Latest replies

*1ST TGT ACHIEVED IN DRREDDY AT 3898, PROFIT RS.11,000 PER LOT*
N
Reputation: 3,975 • Jul 8 2:13 AM
Nifty in overbought state, but make fresh shorts only if it breaks 10,300: Sacchitanand Uttekar
Technically the index has been scaling higher with narrow ranged candles but the momentum indicators are diverging & indicating lack of strength.
Moneycontrol
Like
Reply

Type
Buy
Instrument
DRREDDY
Entry Price
₹3,838
Price@Trade
₹3,838.95
Target Price
₹3,890
Stop Price
₹3,800
Valid Till
Jul 14, 2020 3:20 AM
Margin
₹383,800 approx for 100 Qty
Status
Target Achieved
Exit Price
₹3,890
Net P&L
+₹5,200 (+1.35%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 7 7:44 AM

Update
Trade Entered
Entry Price
₹3,838
TrackerBot @trackerbot
Jul 8 3:07 AM

Update
Target Achieved
Exit Price
₹3,890
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    21-May-20Prabhudas LilladherAccumulate4,326
    21-May-20ICICIdirect.comBuy4,615
    21-May-20Nirmal BangSell3,647
    29-Jan-20HDFC SecuritiesNeutral3,440
    29-Jan-20Karvy Stock BrokingHold3,378
    DRREDDY Brokerage Price Target
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 103899.739573883.23905.45
    Jul 838313944.738313886.7
    Jul 73894.9391938143823.5
    Jul 63925394038773892
    Jul 339403967.9539103921.45
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹3,969.65
    30 Day Moving Average₹3,985.36
    50 Day Moving Average₹3,927.43
    100 Day Moving Average₹3,602.35
    200 Day Moving Average₹3,232.52
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 8 2:13 AM
    Nifty in overbought state, but make fresh shorts only if it breaks 10,300: Sacchitanand Uttekar
    Moneycontrol
    NewsBot
    Jul 6 7:48 AM
    Overall performance may be quite volatile in FY21 due to coronavirus: Dr Reddy's Laboratories
    Moneycontrol
    NewsBot
    Jul 1 6:03 AM
    Fujifilm to partner with Dr Reddy's to sell Avigan overseas as COVID-19 treatment
    Moneycontrol
    NewsBot
    Jun 28 7:18 AM
    Expect to launch 25 products in US this fiscal: Dr Reddy's Laboratories
    Moneycontrol
    NewsBot
    Jun 15 4:38 AM
    Dr Reddy's secures deal with Gilead to produce COVID-19 drug; share price rises 3%
    Moneycontrol
    NewsBot
    Jun 13 10:43 AM
    Coronavirus drug | Dr Reddy's inks pact with Gilead Sciences to manufacture remdesivir
    Moneycontrol
    NewsBot
    Jun 10 10:13 AM
    Dr Reddy's completes the acquisition of Wockhardt's select business divisions
    Moneycontrol
    NewsBot
    Jun 10 12:48 PM
    Hot Stocks | Tech Mahindra, Dr Reddy's Labs, UBL can give up to 11% return in short term
    Moneycontrol
    NewsBot
    May 28 9:38 AM
    Dr Reddy's gets inspection closure report from USFDA for Telangana facility
    Moneycontrol
    NewsBot
    May 23 5:48 AM
    Buy Dr Reddy's Laboratories; target of Rs 4615: ICICI Direct
    Moneycontrol
  • DRREDDY - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020